The August 2026 trial of Inman v. Mead Johnson & Company, LLC, et al. will be the first federal bellwether case to go to trial in MDL 3026 against Mead Johnson, the maker of Enfamil Premature infant formula. For families with pending or potential NEC cases, this is the single most consequential litigation event of 2026. Win or lose, the Inman verdict will reshape settlement dynamics, set the template for subsequent federal Mead Johnson cases, and influence the trajectory of the broader litigation across both federal and state courts.
This guide walks through what's at stake, what the parties will present, what the verdict could mean for the broader pool, and what NEC families should be doing as the trial approaches.
The Federal Bellwether Picture Going Into Trial
As covered in our June 2026 MDL update, the federal bellwether record going into Inman is mixed:
- Abbott has won the first three federal bellwether cases on summary judgment. Each was dismissed before reaching a jury, on the court's finding that the plaintiffs had not presented sufficient evidence to send the case forward.
- Mead Johnson's summary judgment motion was denied in the first federal bellwether against the Enfamil maker. The Illinois federal court found that the plaintiff had presented enough evidence to send the case to a jury — meaning Inman will be the first federal verdict in MDL 3026.
The denial of Mead Johnson's summary judgment motion is itself significant. It tells us the court has identified evidence of duty, breach, causation, and damages sufficient to allow a reasonable jury to find for the plaintiff. The trial determines whether the actual jury agrees.
What the Plaintiff Will Present
The plaintiff's case in Inman is expected to draw from the same evidence framework that has succeeded in the state court trials against Abbott:
The science of cow's-milk-based formula and NEC
The Cochrane systematic reviews, the randomized controlled trials, and the published epidemiologic evidence linking cow's-milk-based premature formula to elevated NEC risk in preterm infants. See our companion guide on why cow's-milk-based formula causes NEC.
The AAP recommendation
The American Academy of Pediatrics' recommendation that pasteurized donor human milk is the preferred alternative to cow's-milk-based formula for very-low-birth-weight infants when mother's own milk is unavailable. See our companion guide on donor milk programs and NEC prevention.
The internal Mead Johnson documents
What Mead Johnson knew about NEC risk and when, drawn from internal corporate documents produced in discovery.
The failure-to-warn theory
Whether Mead Johnson's product labeling, marketing materials, and communications with NICU practitioners adequately disclosed the NEC risk to allow informed treatment decisions.
The Inman child's medical record
The specific NICU course of the Inman child, including the timing of Enfamil Premature feeding, the development of NEC, the staging (medical vs. surgical — see our surgical vs. medical NEC distinction guide), and the long-term consequences.
What Mead Johnson Will Present
Mead Johnson's defense is expected to draw on the same themes that have informed Abbott's successful summary judgment defenses:
Federal preemption
The argument that FDA regulation of infant formula labeling preempts state-law failure-to-warn claims. This has been a centerpiece of the manufacturers' defense in both federal and state cases.
Causation alternatives
The argument that NEC is multifactorial — prematurity itself, bacterial colonization, ischemia, and other factors all contribute — making it difficult to attribute any individual case to formula specifically.
The medical decision-making context
The argument that NICU clinicians, not Mead Johnson, made the decision to feed Enfamil, and that those clinicians were aware of the relevant tradeoffs. This is a "learned intermediary" argument familiar from other pharmaceutical and medical product cases.
Compliance with the standard of care for infant formula
The argument that Mead Johnson's product meets FDA requirements for premature infant nutrition and that the company has done what's required of a responsible manufacturer.
Why This Trial Matters Beyond the Individual Case
The Inman verdict is a directional signal, not a binding precedent. A bellwether verdict does not control the outcome of other individual cases. But it shapes how both sides value the broader pool of cases, what subsequent trials will look like, and whether settlement discussions begin in earnest.
If the plaintiff wins
- Settlement pressure on Mead Johnson increases substantially.
- Other federal Mead Johnson plaintiffs gain leverage in their own cases.
- State court plaintiffs cite the federal verdict in their own proceedings.
- The plaintiffs' bar accelerates filing of similar cases.
- Reckitt Benckiser (Mead Johnson's parent company) faces escalating contingent liability disclosures in its earnings reports.
If the defense wins
- The federal Mead Johnson cases continue but face higher evidentiary burdens.
- The state court verdicts remain as a separate track of leverage for plaintiffs.
- The plaintiffs' bar reassesses which cases to prioritize.
- Settlement discussions, if any, focus on weaker cases and avoid the strongest precedent.
If the verdict is mixed
Most jury verdicts in product liability cases involve specific findings on duty, breach, causation, and apportionment. A finding for the plaintiff on liability but with reduced damages, or a finding for the defense on one theory but with leverage retained on another, would produce a more nuanced settlement dynamic. Both sides usually find something to use.
Timeline Expectations
- Late July 2026: Pretrial motions, jury questionnaires, and final witness designations.
- Early August 2026: Jury selection. Federal product liability cases typically allow several days for selection given the high public profile of the litigation.
- Mid-to-late August 2026: Opening statements, plaintiff's case-in-chief.
- Late August / early September 2026: Defense case, rebuttal, closing arguments.
- Early September 2026: Jury deliberations and verdict.
Federal bellwether trials of this scope typically run three to five weeks. Whatever the verdict, expect post-trial motions (renewed motions for judgment as a matter of law, motions for new trial) and likely appeals from the losing side.
What NEC Families Should Be Doing Now
For families with pending or potential NEC cases, the period before the Inman trial is the right time to act, not to wait:
- Get the case filed if it isn't already. Statutes of limitations continue to run regardless of the bellwether schedule. Families who wait for the Inman verdict to decide whether to file may find their cases time-barred.
- Document the formula identification clearly. Whether the case is Similac-based or Enfamil-based affects which federal bellwether wave it belongs to. See our companion guide on which formula was your baby given.
- Preserve medical records. Hospital record retention policies vary; NICU records from 2018-2024 are often still recoverable but won't be indefinitely.
- Consider state court filing. State court NEC trials have produced very different outcomes from federal summary judgment dispositions. Where federal court might dismiss, state court may not.
- Stay in touch with counsel about the bellwether picture. The August trial will shape what comes next. Cases that are filed and being worked up before the verdict are positioned to benefit from whatever momentum follows.
If You Are Considering an NEC Case
Free, confidential case review. We focus the first conversation on the diagnosis, formula identification, and whether your state's filing window is still open. We handle both federal and state court cases.
- Read the prior June 2026 MDL update: NEC MDL June 2026 Update.
- See if your case fits the profile: Do I Qualify for an NEC Lawsuit?
- Read about NEC and formula science: Why Cow's-Milk-Based Formula Causes NEC.
- Read about which formula your baby was given: Similac vs. Enfamil Identification.
Free case review. No Fees Unless We Recover Money for You.
Sources
- U.S. District Court, Northern District of Illinois — MDL 3026 docket (In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation). ilnd.uscourts.gov
- BusinessWire / Levin Papantonio — "Trial Set in NEC Multidistrict Litigation Against Reckitt Benckiser's Mead Johnson." businesswire.com
- Judicial Panel on Multidistrict Litigation — MDL 3026 status and docket. jpml.uscourts.gov
- American Academy of Pediatrics — Policy statement on donor human milk for high-risk infants. publications.aap.org
- Cochrane Database of Systematic Reviews — Formula vs. donor breast milk for feeding preterm or low birth weight infants. cochranelibrary.com
- U.S. FDA — Infant formula regulations and guidance. fda.gov